Platform

In addition to its lead technology, ECT-001, ExCellThera has a broad pipeline of other programs supported by a development platform and a portfolio of proprietary molecules. These pre-clinical programs include gene therapy, solid organ tolerization, stem cell mobilization, platelet production, adult tissue regeneration and antineoplastic agents.